ASCENTAGE-B (06855) Unveils Four Preclinical Advances at 2026 AACR Annual Meeting, Highlighting Potential of Multiple Combination Therapies

Stock News

Apr 20

ASCENTAGE-B (06855) announced that it will present four preclinical research findings in poster sessions at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference is scheduled to take place from April 17 to April 22, 2026, in San Diego, California, USA.

The poster presentations will cover three of the company's drug candidates. These include the proprietary Class 1 novel drug Olverembatinib (brand name: Nirlivek®; R&D code: HQP1351), a BCR-ABL inhibitor; APG-2449, a triple tyrosine kinase inhibitor targeting FAK/ALK/ROS1; and APG-5918, a PRC2/EED inhibitor.

A key highlight is the demonstration of Olverembatinib's potential beyond chronic myeloid leukemia (CML), showcasing new applications in areas such as endometrial cancer (EC) and mantle cell lymphoma (MCL), as well as combination therapy strategies with BTK inhibitors.

Furthermore, the company's research on APG-2449 for BRAF-mutant tumors and on APG-5918 for small cell lung cancer underscores its strategic focus on overcoming drug resistance mechanisms and exploring combination treatment approaches.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1169155551"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169155551\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169155551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 07:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169155551","market":"hk","top_or_hot":-1,"title":"ASCENTAGE-B (06855) Unveils Four Preclinical Advances at 2026 AACR Annual Meeting, Highlighting Potential of Multiple Combination Therapies","media":"Stock News","content":"<p>ASCENTAGE-B (06855) announced that it will present four preclinical research findings in poster sessions at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference is scheduled to take place from April 17 to April 22, 2026, in San Diego, California, USA.</p>\n<p>The poster presentations will cover three of the company's drug candidates. These include the proprietary Class 1 novel drug Olverembatinib (brand name: Nirlivek®; R&D code: HQP1351), a BCR-ABL inhibitor; APG-2449, a triple tyrosine kinase inhibitor targeting FAK/ALK/ROS1; and APG-5918, a PRC2/EED inhibitor.</p>\n<p>A key highlight is the demonstration of Olverembatinib's potential beyond chronic myeloid leukemia (CML), showcasing new applications in areas such as endometrial cancer (EC) and mantle cell lymphoma (MCL), as well as combination therapy strategies with BTK inhibitors.</p>\n<p>Furthermore, the company's research on APG-2449 for BRAF-mutant tumors and on APG-5918 for small cell lung cancer underscores its strategic focus on overcoming drug resistance mechanisms and exploring combination treatment approaches.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCENTAGE-B (06855) Unveils Four Preclinical Advances at 2026 AACR Annual Meeting, Highlighting Potential of Multiple Combination Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCENTAGE-B (06855) Unveils Four Preclinical Advances at 2026 AACR Annual Meeting, Highlighting Potential of Multiple Combination Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-20 07:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCENTAGE-B (06855) announced that it will present four preclinical research findings in poster sessions at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference is scheduled to take place from April 17 to April 22, 2026, in San Diego, California, USA.</p>\n<p>The poster presentations will cover three of the company's drug candidates. These include the proprietary Class 1 novel drug Olverembatinib (brand name: Nirlivek®; R&D code: HQP1351), a BCR-ABL inhibitor; APG-2449, a triple tyrosine kinase inhibitor targeting FAK/ALK/ROS1; and APG-5918, a PRC2/EED inhibitor.</p>\n<p>A key highlight is the demonstration of Olverembatinib's potential beyond chronic myeloid leukemia (CML), showcasing new applications in areas such as endometrial cancer (EC) and mantle cell lymphoma (MCL), as well as combination therapy strategies with BTK inhibitors.</p>\n<p>Furthermore, the company's research on APG-2449 for BRAF-mutant tumors and on APG-5918 for small cell lung cancer underscores its strategic focus on overcoming drug resistance mechanisms and exploring combination treatment approaches.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1169155551","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169155551","pubTimestamp":1776640579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCENTAGE-B (06855) announced that it will present four preclinical research findings in poster sessions at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","06855":"亚盛医药-B","AAPG":"亚盛医药","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"亚盛-B(06855)在2026年AACR年会上公布四项临床前进展，凸显多种联合疗法潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAPG":1,"06855":1},"content_text":"ASCENTAGE-B (06855) announced that it will present four preclinical research findings in poster sessions at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference is scheduled to take place from April 17 to April 22, 2026, in San Diego, California, USA.\nThe poster presentations will cover three of the company's drug candidates. These include the proprietary Class 1 novel drug Olverembatinib (brand name: Nirlivek®; R&D code: HQP1351), a BCR-ABL inhibitor; APG-2449, a triple tyrosine kinase inhibitor targeting FAK/ALK/ROS1; and APG-5918, a PRC2/EED inhibitor.\nA key highlight is the demonstration of Olverembatinib's potential beyond chronic myeloid leukemia (CML), showcasing new applications in areas such as endometrial cancer (EC) and mantle cell lymphoma (MCL), as well as combination therapy strategies with BTK inhibitors.\nFurthermore, the company's research on APG-2449 for BRAF-mutant tumors and on APG-5918 for small cell lung cancer underscores its strategic focus on overcoming drug resistance mechanisms and exploring combination treatment approaches.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}